{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-24-000025","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.590563+00:00","generated_at":"2026-06-02T18:59:59.296343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada Q1 net income $23.5M; Vertex $75M milestone; DMD Phase 1 final cohort dosed; cash runway to Q2 2026","bullets":["Net income $23.5M vs loss ($6.7M) Q1 2023; collaboration revenue $59.1M (up from $25.3M) on Vertex $75M milestone.","Initiated dosing of 4th & final cohort of Phase 1 trial for ENTR-601-44 in DMD exon 44; data readout expected Oct 2024.","Cash, cash equivalents & marketable securities $327.4M as of Mar 31, 2024; cash runway expected through Q2 2026.","On track to submit regulatory apps in Q4 2024 for Phase 2 studies of ENTR-601-44 (DMD exon 44) and ENTR-601-45 (exon 45)."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-24-000025","json":"https://secwatch.observer/filing/0001689375-24-000025.json","markdown":"https://secwatch.observer/filing/0001689375-24-000025.md","text":"https://secwatch.observer/filing/0001689375-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/0001689375-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/trda-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:59:59.296343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab170b03394ccde6a3529cdbea684c73d47bfbe9","claim":"Entrada Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $59.1 million, net income $23.5 million.","evidence_excerpt":"of EEV therapeutic candidates targeting DMD and advance EEV-therapeutic candidates in indications beyond neuromuscular disease. Collaboration Revenue: Collaboration revenue was $59.1 million for the first quarter of 2024, compared to $25.3 million for the same period in 2023. The increase was primarily a result of the clinical advancement milestone achieved in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/0001689375-24-000025-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$59.1 million"},{"label":"Net income","value":"$23.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}